Dr. Reglero is a biochemist and molecular biologist interested in understanding the mechanisms underlying cancer progression and response to therapy. Clara obtained her PhD degree with honors under the supervision of Dr. Federico Mayor at the Severo Ochoa Molecular Biology Center in Spain. Her work about the regulation of GRK2, a protein implicated in breast cancer, was published in several international articles. During her first years of training, Clara also developed a growing interest in the study of the mechanisms of cancer therapeutics and resistance. In 2018, she joined the laboratory of Dr. Adolfo Ferrando at Columbia University as postdoctoral researcher. The Ferrando lab seeks to decipher the oncogenic mechanisms of acute lymphoblastic leukemia (ALL) and translate it into new therapies for patients. In this context, Dr. Reglero is investigating the mechanisms of resistance driven by mutations in the protein NT5C2 in relapsed ALL. Her work will help understanding relapse in ALL and will facilitate the development of new therapies for the treatment of this disease.